Laboratory trials have found that Generic Rimonabant may aid overweight and obese people to lose weight. It was also found that the drug might lessen the danger of cardiovascular heart disease and diabetes, and be of aid to people who are trying to cease smoking.

Generic Rimonabant hones in on visceral fatty tissue, a section of fatty tissue which stores around internal organs. Lessening this section of fatty tissue has been found to alleviate the production of dangerous substances (such as cholesterol), which alleviate the body managing insulin. This effectively means that Generic Rimonabant can lessen the danger of diabetes and heart disease.

Generic Rimonabant is the anorectic anti-obesity, CB1 Cannabinoid receptor antagonist medicine. The the majority of vital key of its effect is diminution in craving food. Developed by Sanofi-Aventis, Acomplia (generic rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endogenous cannabinoids, such as anadamide, heightens appetite.

Sanofi worked on the premise that if cannabinoids promote appetite, blocking cannabinoid receptors in the brain may lessen appetite. The main cannabinoid (CB1) receptors are understood to play a role in controlling food consumption. To develop appropriate drugs against this target, the human cannabinoid receptor was first cloned and then expressed in cells.

For the majority of people Generic Rimonabant only remained efficient for weight loss for up to roughly 34 weeks, though continuous use of the drug has been shown to keep the weight loss. After ending their use of Generic Rimonabant, the majority of people regained the majority of of the weight they had shed.